Market Intelligence, Clinical Progress, and High-Purity Reagents for NSCLC & Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for c-Met drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | c-Met (MET) ECD-Fc Fusion Protein | |
| Extracellular domain (aa 25-307), HEK293 expressed, >95% purity, Endotoxin <1 EU/μg. Sequence Verified. Native glycosylation. | View c-Met Products | |
| Gene Delivery | c-Met (MET) Premade Lentivirus Particles | |
| Full-length human MET ORF (NM_000245), CMV promoter, Puromycin resistance. For stable cell line generation. | View c-Met Products | |
| Benchmark Ab | Anti-c-Met (Telisotuzumab Biosimilar) | |
| Recombinant human IgG1, sequence verified against clinical reference. Endotoxin controlled. | View c-Met Products | |
| Resistance Mutant | c-Met D1228H Mutant Protein | |
| Kinase domain mutation observed in clinical resistance, >90% purity, Sequence Verified. Also available: Y1230C, L1195V, L1195F. | View c-Met Products | |
| Ligand | HGF (Hepatocyte Growth Factor) | |
| Native glycosylation pattern, sequence verified, for receptor activation assays. | View HGF Products | |
| Validator | c-Met siRNA Set | |
| For knockdown verification and specificity controls. | View c-Met Products | |
| Related Target | EGFR | |
| Bypass resistance pathway; essential for combination therapy and bispecific development strategies. | View EGFR Products | |
| Related Target | AXL | |
| RTK bypass mechanism for acquired resistance to c-Met inhibition; counter-screening essential. | View AXL Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ADC Internalization Efficiency & Conformational Integrity | c-Met ECD-Fc expressed in HEK293 preserves native glycosylation and disulfide bonding; C-terminal AviTag available for site-specific biotinylation compatible with pH-sensitive dye conjugation. |
| Resistance Mutation Profiling (TKI Development) | D1228H, Y1230C, L1195V, L1195F mutants available as recombinant proteins; Mass spec verified; Kinase activity assay ready. |
| Cross-species Toxicology (Cyno/Mouse) | Human/Mouse/Cyno c-Met ECD orthologs with strict sequence homology verification; Conserved epitope mapping for preclinical safety assessment. |
| HGF-dependent vs Independent Activation | Full-length Lentivirus for stable overexpression in BaF3 or CHO cells; Preserves natural conformation for ligand binding and dimerization studies. |
| Off-target Screening (RTK Selectivity) | MET-related RTK panel (RON, AXL, ALK) for cross-reactivity testing; High purity (>95%) proteins ensure specific binding signal. |
| False Positives in Cellular Screens | Validated c-Met siRNA included for target-specificity confirmation. |
Global Clinical Landscape & Future Outlook
The race for c-Met therapeutics is intensifying, with major players shifting focus from first-generation small-molecule TKIs to next-generation ADCs and bispecific antibodies. As selective MET inhibitors such as tepotinib, capmatinib, and savolitinib establish the standard of care for MET exon 14 skipping NSCLC, the next wave of R&D targets MET amplification and acquired resistance mutations (e.g., D1228H, Y1230C, L1195V). Antibody-Drug Conjugates (ADCs) like Telisotuzumab vedotin are advancing through Phase 3 for c-Met overexpressing NSCLC, while bispecific antibodies (e.g., EGFR×c-Met) and PROTACs are emerging as promising modalities to overcome resistance. Liver toxicity and normal-tissue sink effects remain primary clinical hurdles, driving demand for assays that discriminate tumor-selective binding from hepatocyte engagement.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | AbbVie/Genmab (Telisotuzumab), Daiichi Sankyo | c-Met High NSCLC, Gastric Cancer | Internalization Assay (Need high-purity ECD-Fc with native glycosylation) |
| Small Molecule TKI | AstraZeneca/Hutchmed (Savolitinib), Merck (Tepotinib), Novartis (Capmatinib) | MET Exon 14 Skipping, MET-amplified tumors | Resistance Mutant Profiling (Need D1228H/Y1230C mutants vs WT selectivity) |
| Bispecific (EGFR×c-Met) | Johnson & Johnson, Eli Lilly | NSCLC (EGFR-TKI resistant, MET amplified) | Heterodimer Validation (Need Cross-reactive Abs and dual-target binding assays) |
| PROTAC | Cullgen, Biotheryx | Refractory Tumors | Ubiquitination Assay (Need full-length protein expression via Lentivirus) |
Live c-Met R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: